Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer

Figures & data

Table 1 Comparison of general conditions of the patients in the study and control groups

Clinical characteristics	Study group (n=23)	Control group (n=30)	P
Age (years, median value)	52	51	0.82
Pathological type			0.79
Squamous cell carcinoma	17	13
Adenocarcinoma	3	3
Adenosquamous carcinoma	3	4
Stage			0.46
IIb	7	9
IIIa	6	4
IIIb	10	17

Table 2 Comparisons of short-term response rates in the study and control groups [n (%)]

Short-term efficacy evaluation	CR	PR	SD	PD	Total
Study group	18 (78.3%)	2 (8.7%)	1 (4.3%)	2 (8.7%)	23
Control group	15 (50%)	7 (23.3%)	3 (10%)	5 (16.7%)	30
Total	33	9	4	7	53

Figure 1 Kaplan–Meier plots of overall survival rates in the study and control groups.

Figure 2 Kaplan–Meier survival curve analysis of progression-free survival in the study and control groups.

Table 3 Comparisons of acute grade 3 and 4 events in the study and control groups [n (%)]

Group	Hematological system			Impaired liver or kidney function
Leukocyte reduction	Thrombocytopenia	Hemoglobin reduction
Study group (n=23)	9 (39.1%)	1 (4.3%)	4 (17.4%)	2 (8.7%)
Control group (n=30)	21 (70%)	8 (26.7%)	14 (46.7%)	2 (6.7%)
χ^2	5.051	4.600	4.975	0.077
P	0.025	0.076	0.026	1.000

Table 4 Cox regression model of overall survival

Variable	Control	HR	SE	Wald	P	95% CI
Pathological type	Squamous cell carcinoma			1.413	0.493
Adenocarcinoma		0.243	0.488	0.002	0.967	0.023, 2.531
Adenosquamous carcinoma		1.020	1.267	1.286	0.257	0.392, 2.653
Staging	IIb			5.963	0.051
IIIa		0.349	0.468	5.326	0.021	0.061, 2.003
IIIb		0.339	0.933	0.001	0.975	0.135, 0.850
Group	Control group	0.453	0.471	2.833	0.092	0.180, 1.139

Table 5 Cox regression model of progression-free survival

Variable	Control	HR	SE	Wald	P	95% CI
Pathological type	Squamous cell carcinoma			1.468	0.480
Adenocarcinoma		0.242	1.185	1.432	0.231	0.024, 2.471
Adenosquamous carcinoma		0.876	0.491	0.073	0.787	0.334, 2.293
Staging	IIb			4.599	0.100
IIIa		0.360	0.879	1.352	0.245	0.064, 2.015
IIIb		0.404	0.461	3.872	0.049	0.163, 0.996
Group	Control group	0.380	0.479	4.090	0.043	0.148,0.971